[ad_1]
A not too long ago concluded scientific research on the combination of Ayurveda into the administration of COVID-19 has discovered that add-on treatment of sure non-patented classical Ayurveda medicines generated the optimal immune system modulations in high-risk sufferers with diabetes.
The interim evaluation of the research discovered that sufferers who had been below the add-on Ayurveda treatment, together with the usual ICMR guideline-driven remedy, exhibited optimal modulation of interleukin 6 (IL6) in response to SARS-CoV-2 than those that had been below the usual ICMR guideline-driven remedy alone.
IL6 is a cytokine or a class of small proteins that regulates the immune system in the physique with its pro-inflammatory and anti inflammatory properties.
Key biomarker
“The add-on Ayurveda group exhibited IL6 cytokine modulation within seven days of treatment, which is a key biomarker indicating the progress of severity. The integrative care seems to be showing comparative earlier viral clearance. The study also explored the possibility of toxicity due to drug-to-drug interaction, if any, and found that there was no liver and kidney toxicity due to the administration of add-on Ayurveda therapy along with the standard ICMR guideline-driven treatment,” stated Somit Kumar, principal investigator of the research.
It was completed by AVP Research Foundation, Coimbatore, and Stanley Medical College, Chennai, with funding from the Union Ministry of AYUSH and supported by the Tamil Nadu Health Department.
According to investigators, 51 COVID-19 sufferers with a historical past of diabetes accomplished the scientific research registered in the Clinical Trials Registry of India. While 27 sufferers went by the add-on Ayurveda remedy together with the ICMR-recommended remedy, 24 sufferers had standalone ICMR-recommended remedy.
The youngest affected person was aged 34 and the oldest 75. The final affected person was discharged on August 30.
Improving host response
“The focus of the add-on Ayurveda group was on improving the host response to the SARS-CoV-2 infection, where the treatment would modulate the immune response to act optimal to fight the infection, while at the same time not going haywire to induce a ‘cytokine storm’, which is the major reason for death among patients,” Dr. Kumar stated.
“No patient from the add-on Ayurveda group required ICU admission, when one in the standalone treatment group had to be in intensive care. Both groups did not have any casualties,” stated Sujith Eranezhath, one other investigator.
According to the research workforce, which included C. Chaitanya, S. Balagopal and Lakshmi Prabha as investigators, the protocol was based mostly on a dozen classical Ayurveda non-patented medicines, together with Indukantham kashayam, Bharangyadi kashayam, Drakshadi kashayam and Ashtanga choornam.
“The use of classical Ayurveda medicines for the study was at the insistence of P.R. Krishnakumar, managing director of AVP (Coimbatore) Ltd., who passed away last month. He wanted everyone to use these and it should not be AVP’s exclusivity,” stated the investigators.
The research ideated by AVP Research Foundation, in session with consultants, was carried out below the surveillance of the Ethics Committee of Stanley Medical College. Doctors from Stanley Medical College V. Vinodkumar and C. Sridhar, supported by dean P. Balaji, had been additionally a part of the research.
[ad_2]
